Reimbursed Care Access in Mali

Currently classified as a controlled psychotropic substance under Mali's national scheduling and lists of 'substances vénéneuses / stupéfiants', with no authorized medical use outside approved clinical research. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside approved clinical research. Mali's drug-control framework implements UN conventions and restricts MDMA; possession, trafficking and import/export are criminalized. # #

Esketamine (the S-enantiomer marketed elsewhere as a licensed antidepressant) is not documented as an authorized marketed product in Mali and there is no evidence of national regulatory approval or public reimbursement for esketamine-based therapies. Mali's pharmaceutical regulation and supply oversight are handled through the Ministry of Health and the Direction de la Pharmacie et du Médicament (DPM); novel psychopharmacologic products that have not been registered locally are not covered by state insurance systems and would only be accessible via import authorization for clinical research or special import procedures. # #

Ketamine is an established anesthetic/analgesic present in Mali's pharmaceutical supply and appears in national consumption statistics and pharmacopeia/procurement reporting, indicating routine medical use in hospitals and surgical/trauma care. #

Regulatory framework and oversight: Mali regulates controlled medicines via national laws implementing UN drug conventions (notably Loi n°01-018/AN-RM and implementing decrees) and by ministerial structures including the Ministry of Health and the Direction de la Pharmacie et du Médicament (DPM). Controlled-substance lists and decrees that govern medical availability and distribution include specific tables of controlled substances used to limit diversion and specify prescription/dispensing rules. # #

Access, indications and reimbursement: In practice ketamine is used in Mali for its licensed indications (anesthesia, analgesia) and occasionally in off-label settings by clinicians (e.g., severe pain, emergency medicine). There is no public evidence of a formal, nationally funded reimbursement policy for ketamine when used for psychiatric indications (e.g., treatment‑resistant depression); Mali's public health financing is limited, and most specialty or novel off-label uses are paid out‑of‑pocket or provided within private clinics or donor‑funded programs. Authorization for ketamine procurement and distribution follows controlled-substance procedures (special procurement/recordkeeping) rather than a specific national mental-health reimbursement pathway. # #

Regional/state nuance: Mali does not operate a federated state-by-state healthcare reimbursement system; instead, national-level rules apply across the country, with variability in practical access between urban tertiary hospitals (Bamako) and rural facilities where supply and trained anesthesia/psychiatry personnel are limited.

Currently classified as a strictly controlled substance under Mali's national schedules (listed among substances du Tableau B in national decrees), with no authorized medical use outside approved clinical research. Possession, production and trafficking are criminal offenses subject to national drug laws. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside approved clinical research. As an atypical tryptamine it falls under broad psychotropic substance controls implemented in Mali. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside approved clinical research. There is no regulatory pathway or reimbursement for ibogaine in Mali. # #

Currently classified as a strictly controlled substance (DMT-containing preparations are controlled) under national scheduling; traditional plant brews containing DMT/other controlled tryptamines are not authorized for medical use outside approved research and are subject to the same prohibitions on possession and trafficking. # #

Explicitly listed among controlled substances in Mali's decrees and therefore classified as a controlled psychotropic/stupefiant with no authorized medical use outside approved clinical research. Possession, cultivation (where applicable), manufacture and trafficking are prohibited. #

Currently classified as a strictly controlled substance category under Mali's drug-control framework (substituted phenethylamines and novel psychoactive substances are covered by broad scheduling measures) with no authorized medical use outside approved clinical research. Enforcement targets importation and trafficking per customs and narcotics law. # #